Revelation Biosciences Inc REVB.OQ REVB.O is expected to show no change in quarterly revenue when it reports results on August 7 (estimated) for the period ending June 30 2025
LSEG's mean analyst estimate for Revelation Biosciences Inc is for a loss of $4.45 per share.
The one available analyst rating on the shares is "buy".
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Revelation Biosciences Inc is $512.18, about 99.5% above its last closing price of $2.54
This summary was machine generated August 5 at 11:08 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)